An October 2024 research report from IQVIA found that many of the drugs chosen for negotiation under the IRA already had established copays, which will either stay the same or increase under the new provisions. As a result, the IRA could end up costing patients more, rather than less. Read a summary and access the full report here:
关于我们
Since 2007, We Work For Health (WWFH) has been bringing together national and local business leaders, labor, biopharma, patient advocacy and other healthcare-related stakeholders. WWFH is dedicated to promoting policies and initiatives that not only foster innovation and facilitate the delivery of lifesaving or life-enhancing medicines, but also value both the workforce and significant contributions of the biopharmaceutical sector to economies at the national, state and local levels.
- 网站
-
weworkforhealth.org
We Work For Health的外部链接
- 所属行业
- 生物技术研究
- 规模
- 1 人
- 类型
- 非营利机构
We Work For Health员工
动态
-
Because of the #IRA, seniors are facing higher healthcare costs and reduced access to innovative medicines. Read more here:
-
Center for Strategic and International Studies (CSIS) is releasing a report on protecting #IntellectualProperty for national security. Join the launch & discussion with stakeholders on March 28 at 2:00 PM ET
-
American innovation is only as strong as the laws that protect it. If we want to continue to be a leader in the biopharmaceutical industry, we must protect #IPrights. Watch this video from Council for Innovation Promotion:
-
The IRA price control program is harmful to patients, and, as our Executive Director Dan Leonard stated, "the impact is primarily on seniors."?See a recording of the full IQVIA webinar here: https://lnkd.in/e7U3nb8k
-
As Congress works on the #EPICAct, CMS should focus the MPDN program on drugs with 3-5 years of patent exclusivity.
-
Last October, an IQVIA study revealed that patients are unlikely to see any out-of-pocket savings from the IRA. In fact, this study found that some patients may pay more. See our press release on the study here: